NIM
AVBP icon

NEOS Investment Management’s ArriVent BioPharma AVBP Stock Holding History

NEOS Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,487
Closed -$654K – 662
2025
Q4 		$654K Buy
+32,487
New +$676K ﹤0.01% 586

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NEOS Investment Management's AVBP Position: Q1 2026 in Review

NEOS Investment Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 32,487 shares — an estimated $654K sold.

NEOS Investment Management first reported a position in AVBP in Q4 2025 and held it in 1 quarter. The position peaked at $654K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • NEOS Investment Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 32,487 ArriVent BioPharma shares in Q1 2026, an estimated $654K.
  • NEOS Investment Management first reported a position in ArriVent BioPharma in Q4 2025 and held it in 1 quarter.
  • NEOS Investment Management's ArriVent BioPharma position peaked at $654K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.